Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Sagimet Biosciences Inc.NASDAQ: SGMT
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments falls 15.0% from a year ago
Short-term investments stood at $67.91M at the end of Q1 FY2026, down 15.0% from a year earlier and down 13.0% from the prior quarter. Over 3 fiscal years it compounded at +34.4% a year.
Context
- Short-term investments amounted to 63.0% of total assets at the end of Q1 FY2026, up 8.4 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -15.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 78.1M USD
- Year-over-year change
- +3.6%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 78.1M | +3.6% |
| FY2024 | 2024-12-31 | 75.41M | +281.7% |
| FY2023 | 2023-12-31 | 19.76M | -38.6% |
| FY2022 | 2022-12-31 | 32.19M | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 short-term investments of $67.91M is the 7th highest of the 11 companies compared; the peer median is $97.07M.
- Its year-over-year change of -15.0% is the 2nd highest of 7, against a peer median of -41.1%.
- Short-term investments amounts to 63.0% of total assets for SGMT, versus a peer median of 23.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $195.48M | +189.1% | +69.1% | 83.0% | |
| Mar 2026 | $178.42M | -43.3% | +12.7% | 53.2% | |
| Mar 2026 | $176.69M | -42.3% | — | 66.2% | |
| Mar 2026 | $109.37M | — | +10.3% | 0.1% | |
| Mar 2026 | $98.17M | -39.1% | +87.5% | 44.8% | |
| Mar 2026 | $95.97M | -39.9% | -35.7% | 43.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $67.91M | -15.0% | +34.4% | 63.0% |
| Mar 2026 | $1.19M | -88.4% | — | 3.6% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding SGMT) | $97.07M | -41.1% | +12.7% | 23.4% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.